Profile data is unavailable for this security.
About the company
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
- Revenue in USD (TTM)0.00
- Net income in USD-24.83m
- Incorporated2017
- Employees2.00
- LocationNRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
- Phone+1 (484) 254-6134
- Fax+1 (302) 575-1642
- Websitehttps://www.nrxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 12.41m | 7.00 | -- | 3.08 | -- | 317.11 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 12.59m | 22.00 | -- | 1.04 | -- | 179.92 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Protext Mobility Inc | 750.00 | -2.21m | 13.19m | 4.00 | -- | -- | -- | 17,582.44 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
Biomx Inc | 0.00 | -26.25m | 13.22m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
Apollomics Inc | 0.00 | -57.11m | 13.22m | 45.00 | -- | 0.6337 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
OpGen Inc | 1.96m | -22.39m | 13.37m | 100.00 | -- | -- | -- | 6.80 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
Evaxion Biotech A/S - ADR | 3.30m | -11.46m | 13.49m | 49.00 | -- | -- | -- | 4.10 | -16.80 | -16.80 | 0.8311 | -- | -- | -- | -- | 67,244.90 | -- | -100.11 | -- | -131.65 | -- | -- | -347.86 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.52m | 2.00 | 3.48 | 0.2847 | 3.01 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
Sensei Biotherapeutics Inc | 0.00 | -29.67m | 13.58m | 28.00 | -- | 0.26 | -- | -- | -1.18 | -1.18 | 0.00 | 2.08 | 0.00 | -- | -- | 0.00 | -39.73 | -47.03 | -42.67 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0232 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Hcw Biologics Inc | 3.92m | -38.37m | 13.63m | 45.00 | -- | -- | -- | 3.47 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
NRX Pharmaceuticals Inc | 0.00 | -24.83m | 13.65m | 2.00 | -- | -- | -- | -- | -1.62 | -1.62 | 0.00 | -1.70 | 0.00 | -- | -- | -- | -197.97 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -189.12 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
Aspira Women's Health Inc | 8.92m | -15.95m | 13.80m | 64.00 | -- | -- | -- | 1.55 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
Cingulate Inc | 0.00 | -19.10m | 14.52m | 13.00 | -- | 1.14 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
Inhibitor Therapeutics Inc | 0.00 | -3.02m | 14.65m | 3.00 | -- | 3.54 | -- | -- | -0.0175 | -0.0175 | 0.00 | 0.024 | 0.00 | -- | -- | 0.00 | -34.83 | 27.48 | -34.99 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
AIM ImmunoTech Inc | 201.00k | -28.05m | 14.72m | 26.00 | -- | 2.16 | -- | 73.21 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 240.32k | 2.24% |
AdvisorShares Investments LLCas of 30 Jun 2024 | 108.09k | 1.01% |
Geode Capital Management LLCas of 30 Jun 2024 | 65.66k | 0.61% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 29.08k | 0.27% |
Virtu Americas LLCas of 30 Jun 2024 | 17.04k | 0.16% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 16.72k | 0.16% |
One Wealth Management Investment & Advisory Services LLCas of 30 Sep 2024 | 15.04k | 0.14% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 4.40k | 0.04% |
RBC Capital Markets LLC (Investment Management)as of 30 Jun 2024 | 4.00k | 0.04% |
Tower Research Capital LLCas of 30 Jun 2024 | 3.33k | 0.03% |